Reducing Point-of-Care Transfusion Requirements With Prolonged Desmopressin in High-Bleeding-Risk Cardiac Surgery: A Multicentre Randomized Controlled Trial (REDES-BLEED)

Rationale
Bleeding after cardiac surgery is a complication that might result in increased morbidity, mortality, and cost of cardiac surgery by 1.76 (confidence interval (CI), 1.64-1.90) times and a median increase in costs by Australian $33,338 (CI, $21,943-$38,415) [1]. Strategies and techniques to reduce postoperative bleeding in identified high-risk patients for bleeding after cardiac surgery might improve outcomes and resource utilization.
Desmopressin (DDAVP) is used as a hemostatic agent to prevent and treat bleeding in patients with mild hemophilia patients with von Willebrand's deﬁciency through stimulating the release of von Willebrand factor from endothelial cells.
Previous studies showed controversial results in terms of reduced transfusion requirements in patients with low risk for bleeding with post cardiopulmonary bypass (CPB) bleeding following prophylactic infusing desmopressin over 10 to 15 minutes after induction of anesthesia or protamine administration due to its positive effects on the coagulation system responsible for such bleeding. Contradictory, prophylactic desmopressin use demonstrated fewer transfusion requirements in patients treated with antiplatelets, which raises the need to examine its efficacy in high-risk cardiac surgery patients for perioperative bleeding. These controversial results might be attributed to delayed administration of desmopressin after evolving CPB-associated thrombocytopenia, platelet dysfunction, coagulation factor consumption and dilution, hyperfibrinolysis, and hypofibrinogenemia [2]
Concerns were raised about the associated transient decreases in systemic vascular resistance and blood pressure after desmopressin administration following discontinuing CPB and administering protamine, which might be related to the rapid infusion rate during the critical surgery stage.
The cost of a single dose of Desmopressin 0.3 ug/kg for a patient with an average weight of 70 Kg is about 82US$ which is cheaper than the alternative hemostatic agents proved to be effective in reducing bleeding and transfusion needs after cardiac surgery (e.g., fibrinogen concrete (average of 3 g = 1,167US$) and prothrombin complex concentrate (6,255US$ considering low fixed dosfixed-doseof 1040 IU F IX).
It is yet unclear if extended infusions of desmopressin started earlier before the development of CPB-associated coagulopathy and platelets dysfunction from anesthesia induction time and continued to the end of CPB before protamine administration would offer an "efficacy," "safety, and "cost-effective" benefits over placebo in patients with high risks for bleeding after cardiac surgery terms of the need for transfusion, cumulative postoperative 48-hour chest tube outputs, need for reoperation, thrombotic complications, 30-day mortality, hemodynamic stability, and urine output during and after completing infusion, and costs of the study drug and allogenic transfusion requirement. That raises the need to examine its impact on these crucial clinical outcomes.
Objective
The primary objective of this prospective multicentre randomized clinical trial (RCT) is, compared with placebo, to examine the impact of prolonged infusion desmopressin on reducing postoperative bleeding and the need for allogenic allogeneic transfusion in high-bleeding-risk cardiac surgery patients scheduled for elective cardiac surgical procedures using CPB. Secondary objectives include comparing placebo and desmopressin in terms of safety and cost-effectiveness.
Hypothesis
It is hypothesized that extended 'desmopressin' infusion compared to 'placebo' results in less postoperative bleeding and transfusion needs (more effective) and leads to less hemodynamic compromise (safer) and cheaper (cost-effective) in high-risk cardiac surgery patients.

开始日期2025-07-01

申办/合作机构

Imam Abdulrahman Bin Faisal University

[+1]

CTIS2023-507254-32-00

/ Recruiting临床3期IIT

DASSOH - Systematic use of DDAVP to prevent serum sodium overcorrection in severe hyponatremia : a multicenter open-label randomized controlled trial - APHP220676

开始日期2024-12-17

申办/合作机构

Assistance Publique Hopitaux De Paris

NCT06020495

/ Recruiting临床3期IIT

Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia: a Multicenter Open-label Randomized Controlled Trial

ICU patients with severe hyponatremia and a high risk of rapid SNa overcorrection.

开始日期2024-12-17

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

100 项与醋酸去氨加压素相关的临床结果

登录后查看更多信息

100 项与醋酸去氨加压素相关的转化医学

登录后查看更多信息

100 项与醋酸去氨加压素相关的专利（医药）

登录后查看更多信息

5,861

项与醋酸去氨加压素相关的文献（医药）

2025-12-31·RENAL FAILURE

Desmopressin and bleeding risk in high-risk native kidney biopsy: updated meta-analysis of RCTs and observational studies

Review

作者: Bertuol Junior, Vanderlei Carlos ; Manfro, Roberto Ceratti ; Steckert, Gabriela Vieira ; Manfro, Arthur Gus ; Martins FIlho, Cleuber Gea ; Sartori Pacini, Gabriel ; Bauer, Andrea Carla ; Asnis Schuchmann, Renata

BACKGROUND:

Desmopressin (DDAVP) is sometimes used prophylactically to mitigate bleeding complications associated with kidney biopsy in patients with impaired kidney function, although its efficacy remains uncertain. We conducted a systematic review and meta-analysis to evaluate whether DDAVP reduces bleeding complications in high-risk patients undergoing native kidney biopsy.

METHODS:

We searched PubMed, EMBASE, Cochrane, and ClinicalTrials.gov through April 2025 for randomized or observational studies comparing DDAVP to placebo or no intervention in adults with eGFR <60 mL/min/1.73 m². The primary outcome was overall bleeding. Pooled risk ratios (RRs) were estimated using a random-effects model. Subgroup and sensitivity analyses, including leave-one-out diagnostics, were performed.

RESULTS:

Nine studies (n = 2,470) were included. The pooled RR for bleeding was 0.61 (95% CI, 0.33-1.11), with substantial heterogeneity (I² = 73.6%). Observational studies showed a significant reduction in bleeding (RR = 0.52; 95% CI, 0.44-0.61; I² = 0%), whereas RCTs did not (RR = 0.87; 95% CI, 0.10-7.69; I² = 89.3%). Sensitivity analysis identified one outlier; its exclusion reduced heterogeneity (I² = 18.3%) and yielded a pooled effect (p < .0001). Safety outcomes were infrequently reported but appeared to be mild.

CONCLUSIONS:

While the overall pooled analysis did not reach statistical significance, results from observational studies and sensitivity analyses suggest a potential protective effect of DDAVP in reducing bleeding after kidney biopsy in high-risk patients. However, given the low certainty of evidence, these findings should be considered exploratory and hypothesis-generating. Larger, well-powered RCTs are warranted to confirm these findings and to better characterize safety.

2025-12-01·CHILDS NERVOUS SYSTEM

Intracranial lobar germinoma presenting with refractory hypernatremia

Article

作者: Saini, Jitender ; Arivazhagan, A ; Sipani, Mahak ; Shashidhar, Abhinith ; Birua, Gyani Jail Singh ; Rao, Shilpa

Central nervous system germ cell tumours are most commonly seen in the midline structures. Eccentric germinomas are rare but can be found in the basal ganglia, lobar, brainstem, and cranial vault. We present a 14-year-old boy who presented with signs and symptoms of overt diabetes insipidus and a radiological diagnosis of left frontal high-grade glioma. Confirmative histopathology revealed germinoma. The patient had a resolution of hypernatremia post-surgery and maintained normal sodium homeostasis on a single dose of 0.1 mg of tablet desmopressin. This paper showcases a rare case of an eccentric central nervous system germinoma in a young male patient presenting with Diabetes Insipidus without any apparent sellar or suprasellar involvement.

2025-10-01·PEDIATRIC NEPHROLOGY

Efficacy of desmopressin and enuresis alarm in the treatment of monosymptomatic nocturnal enuresis: a multicenter prospective randomized controlled study

Article

作者: Zhang, Yanping ; Zhai, Rongqun ; Wang, Yihe ; Yang, Jing ; Wen, Jian Guo ; Li, Qingli ; Zhou, Chaoming ; Zhang, Huiqing ; Li, Shuai ; Shao, Sida ; Lv, Lei ; Wu, Guoxing ; Wang, Qingwei ; Wen, Yibo ; Lu, Wei

BACKGROUND:

To compare the therapeutic effect of desmopressin (DDAVP) and enuresis alarm (EA) in treating primary monosymptomatic nocturnal enuresis (MNE) and identified prognostic factors.

METHODS:

A total of 213 children (6-16 years) with MNE were randomized to the DDAVP or EA group at five hospitals in mainland China from January 2019 to December 2023. Comprehensive medical histories were collected, and voiding diaries were maintained for two consecutive weeks. All participants underwent 12-week follow-up evaluations, with therapeutic outcomes assessed at the endpoint. Children achieving complete response were monitored for relapse for an additional 3 months post-treatment.

RESULTS:

After excluding 28 patients (16 lost to follow-up, 12 incomplete diaries), 185 completed the study (63.24% male, mean age 10.25 ± 2.36 years). The loss to follow-up rate in the EA group was higher than in the DDAVP group (11.71% vs. 2.94%, P < 0.05). Ninety-four children were treated with EA and 91 children with DDAVP. After 12 weeks, there was no significant difference in the therapeutic effect between the DDAVP and EA group (P > 0.05). Relapses occurred in 1/30 children in the EA group and 6/30 children in the DDAVP group (P < 0.05). Family history (OR = 2.37, 95%CI: 1.16-4.84), enuresis frequency > 4 times/week (OR = 2.30, 95%CI: 1.08-4.89), and reduced bladder capacity (OR = 2.29, 95%CI: 1.12-4.66) were negative prognostic factors.

CONCLUSION:

Both therapies showed comparable short-term efficacy, but EA exhibited superior durability with lower relapse. Family history, severity of enuresis, and reduced bladder capacity are negative prognostic factors for therapeutic effect.

146

项与醋酸去氨加压素相关的新闻（医药）

2025-09-12

·PRNewswire

WFH mobilizes global community to achieve milestone revisions to WHO EML

MONTREAL, Sept. 12, 2025 /PRNewswire/ - A concerted effort by the World Federation of Hemophilia (WFH) and its partners has led to the World Health Organization (WHO) updating its Essential Medicines List (EML) and the Essential Medicines List for Children (EMLc) to better align the EMLs to the international clinical guidelines for the management of hemophilia and von Willebrand Disease (VWD). These revisions will have a positive impact on lives of people with bleeding disorders (PWBDs) everywhere. The WHO EML has a critical role in guiding national governments on the selection and financing of essential medicines for a range of conditions, including hemophilia. These revisions mean that decision makers will be using up-to-date recommendations when making key decisions that will impact treatment for people with hemophilia. "The updates to the WHO EML mean that thousands of PWBDs now have greater hope for a better future. The WFH is proud to have led a united global effort to make this milestone possible. Together, we are shaping a future where our vision of Treatment for All can become a reality." —Cesar Garrido, President, WFH The request to update the WHO EML was built on key revisions that were needed to improve listings for the treatment of hemophilia and VWD. Today, prophylaxis is the internationally recognized standard of care for people with hemophilia. A range of virally safe and effective therapies are available for people with hemophilia and VWD. Conversely, cryoprecipitate (whether pathogen-reduced, PR-Cryo, or not) cannot be used for prophylaxis. Furthermore, cryoprecipitate poses a significant risk of transmission of bloodborne infections. The revisions introduced in the recently published 24th EML and 10th EMLc will help to increase equitable access to safer and more effective therapies for PWBDs worldwide. Outlined below are the critical changes made to the EML and EMLc, in relation to the medicines indicated for treatment of hemophilia and VWD. New medicines added to the EML and EMLc Bi-specific monoclonal antibody, emicizumab, was included on the core list Recombinant FVIII and FIX clotting factor concentrates (CFCs) was included on the core list Revisions made to existing medicines listed on EML and EMLc Plasma-derived FVIII and FIX CFCs were transferred from the complementary to the core list Desmopressin was transferred from the complementary to the core list Medicines or formulations deleted on EML and EMLc Both pathogen-reduced and non-pathogen reduced cryoprecipitate were removed as indications for the treatment of hemophilia and VWD Factor IX Complex (also known as prothrombin complex concentrate (PCC)) was deleted as a therapeutic alternative to FIX CFCs "The WHO's decision to update the Essential Medicines Lists marks a major step forward in ensuring access to modern, effective treatments for people with bleeding disorders worldwide. This milestone was only possible thanks to the strong support and collaboration of scientific and patient advocacy organizations across the world. Together, we have helped align global policy with the best clinical standards, making the EML a strong advocacy tool to countless patients and families in countries that don't have full access to these therapies." —Glenn Pierce, MD, PhD, Vice President, Medical, WFH This milestone for our community was realized thanks to a joint effort led by the WFH, underscoring the wide-reaching commitment across institutions, experts, and organizations to update the EML. The process included the WFH undertaking a two-year-long ongoing direct dialogue with the WHO Headquarters and consulting with the EML Secretariat closely throughout the application process. The WFH was also an active participant at the meeting of the WHO 25th Expert Committee on the Selection and Use of Essential Medicines, and made a statement in favour of updating the guidelines during the public session on May 5, 2025. The WFH also summarized its concerns about the outdated recommendations in "Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List" published in The Lancet Haematology in September 2024. The WFH would like to acknowledge and express its gratitude to its national member organizations (NMOs), expert clinicians, hemophilia treatment centres (HTCs) and scientific and patient advocacy associations from around the globe that supported this endeavour. A joint letter of support addressing the WHO Director General was endorsed by 115 WFH NMOs, while another was signed by over 120 expert clinicians representing every region of the world. Additional individual letters of support came from leading medical and patient associations, including the European Association for Haemophilia and Allied Disorders (EAHAD), the European Haemophilia Consortium (EHC), the International Society on Thrombosis and Haemostasis (ISTH), the Association for Haemophilia and Allied Disorders – Asia Pacific (AHAD-AP), Grupo Cooperativo Latinoamericano de Hemostasia y Trombosis (CLAHT), the Association for the Advancement of Blood and Biotherapies (AABB), the Indian Association for Haemophilia and Allied Disorders (IAHAD), the International Patient Organization for Primary Immunodeficiencies (IPOPI), Rare Diseases International (RDI), the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), the Cerus Corporation, and other organizations. This wealth of support from our NMOs, expert clinicians, partners and collaborating scientific and patient associations is a true testament of how our global bleeding disorders community can come together for a common cause and in service of our shared vision of Treatment for All. The three WFH submissions for the 2025 update of EML and EMLc, respective letters of support and the WFH Statement made at the meeting of the WHO 25th Expert Committee on the Selection and Use of Essential Medicines can be viewed here. To view the WFH publication on "Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List" published in The Lancet Haematology, please click here. To view the recently-published 24th Essential Medicines List and the 10th Essential Medicines List for Children of the World Health Organization (WHO), please click here. About hemophilia and other bleeding disorders In people with bleeding disorders, the blood clotting process doesn't work properly, with the result that they can bleed for longer than normal, and some people may experience spontaneous bleeding into joints, muscles, internal organs or other parts of their bodies which can lead to serious health complications and even be fatal if left untreated. About the World Federation of Hemophilia The World Federation of Hemophilia (WFH) is a non-profit organization dedicated to improving and sustaining care for people with inherited bleeding disorders around the world. At the WFH, national member organizations (NMOs) and health care professionals (HCPs) work together to provide care for people with inherited bleeding disorders around the world. We partner with governments and hemophilia treatment centres to enhance knowledge through training and provide tools they need to identify, support, and treat people living with bleeding disorders in their communities, while promoting global advocacy and collaboration to achieve our common goals. The WFH is founded upon the following core values and organizational principles: patients first, collaboration, integrity, respect, solidarity and excellence. Our vision of Treatment for All is for a world where all people with inherited bleeding disorders have access to care, regardless of their type of bleeding disorder, gender, or where they live. Our mission is to improve and sustain care for people with inherited bleeding disorders around the world. To find out more about the WFH, please visit . Media contact: Neha Suchak Director, Marketing & Communications [email protected] +1 514-875-7944, #2857 SOURCE World Federation of Hemophilia WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-09-11

·国际糖尿病idiabetes

隆敏教授：垂体微腺瘤MDT诊治——从国际标准到中国实践

点击“蓝字”关注我们编者按垂体神经内分泌肿瘤（PitNET）/垂体腺瘤（PA）是颅内最常见的肿瘤之一，多数表现为良性肿瘤的生长特性，但部分具有侵袭性生物学行为。随着诊断技术的进步和WHO分类标准的更新，垂体腺瘤的诊疗理念已从单纯手术治疗转变为多学科协作（MDT）的精准诊疗模式。在8月1~3日召开的第二十八次全军内分泌代谢病学术大会上，来自陆军军医大学第一附属医院内分泌科、重庆市医学高端人才垂体性腺工作室的隆敏教授从垂体瘤分类、研究介绍、垂体微腺瘤临床案例回顾到垂体性腺疾病MDT进行了全面分享，旨在提升多学科协作诊疗水平，优化临床决策流程，为患者提供个体化、精准化的综合治疗方案！一、垂体瘤指南演变及相关学组建设 PitNET/PA是垂体前叶激素产生细胞的克隆性肿瘤增殖。平均发病率约为每年每10万人5.1例。其分类标准经历了重要演变： 2017年：世界卫生组织（WHO）发布第四版《世界卫生组织内分泌肿瘤分类》，包括垂体腺瘤及其他非神经内分泌肿瘤[1]。 2018年：基于国际癌症研究机构（IARC）共识会议及后续专家讨论，明确区分分化型神经内分泌肿瘤（NET，部分系统称类癌）与低分化神经内分泌癌（NEC），二者均表达神经内分泌标志物[2]。 2022年：第五版WHO分类正式将垂体腺瘤归类为神经内分泌肿瘤，采用“垂体神经内分泌肿瘤（PitNET）”命名，所有的PitNET必须根据谱系、细胞类型、所产生的激素以及其他辅助特征进行分类（图1）[3]。 2023年：Tsukamoto T等学者结合第五版分类标准（包括肿瘤行为代码从良性“0”调整为恶性“3”），系统综述了PitNET的影像学诊断策略（MRI/CT/PET）[4]。图1. 根据细胞谱系、类型及特征细化组织学亚型（第五版WHO分类）[3] 中国对垂体瘤的临床认识与诊疗规范经历了持续深化和完善的过程：2015年发布《中国垂体腺瘤外科治疗专家共识》[5]奠定了手术规范治疗的基础框架；2019年针对临床难点推出《中国难治性垂体腺瘤诊治专家共识》[6]着重解决难治性病例的诊疗规范；2022年《中国垂体瘤卒中诊治专家共识》[7]进一步细化急症处理规范。与此同时，国际领域也在不断推进，2024年最新发布的关于儿童和青少年时期垂体腺瘤的诊断和管理的共识指南[8]则聚焦儿童青少年这一特殊人群，形成覆盖全年龄段的完整诊疗体系，体现了从基础治疗向精准化、个体化诊疗的发展轨迹。为规范垂体瘤诊疗标准并提升患者照护质量，垂体学会（Pituitary Society）启动了"垂体瘤卓越中心（PTCOE）"认证标准的制定工作，现已形成PTCOE认证标准体系，为垂体疾病诊疗体系的优化提供了明确方向[9]。国内方面，华山医院“金垂体”的经验以及北京协和医学院几位学者提出的建议[10-12]与国际PTCOE理念相呼应，对我国加强多学科协作、提升垂体促甲状腺激素腺瘤的诊治水平起到了重要促进作用。 MDT作为垂体瘤诊治的科学模式，其核心流程包括：1）通过临床症状和体格检查初步筛查；2）结合激素水平确诊试验明确诊断，包括地塞米松抑制试验、ACTH兴奋试验、奥曲肽抑制试验、低血糖兴奋试验和GnRH/HCG兴奋试验等；3）借助垂体组织活检和奥曲肽显像等技术进行精准分型定位；4）开展全面术前评估；5）实施围手术期多学科协作管理；6）最终实现垂体功能重建的全程规范化诊疗（图2）。图2. 垂体瘤MDT诊治流程重庆市在垂体疾病学科建设方面持续深化专业化发展：2015年，重庆市医学会神经外科分会率先成立垂体瘤学组，标志着垂体疾病外科诊疗的规范化进程正式启动；至2024年，重庆市医学会内分泌学分会完成垂体性腺学组改选，反映了MDT理念在垂体疾病诊治领域的落地实践。2025年获批成立西南内分泌垂体性腺疾病专科联盟，通过协同创新，实现医疗质量提升、资源优化配置，为患者提供精准化、个体化服务。二、垂体瘤临床案例分享病例1 女性，42岁。症状：口干、多饮、多食2年，血糖控制不佳6个月。病史：2型糖尿病，伴血糖控制不佳及骨质疏松，给予胰岛素+瑞格列奈降糖效果欠佳，近6月监测血糖多在10 mmol/L以上。查体：腹型肥胖、满月脸、双侧脸颊发红、水牛背，肘窝可见少许皮肤瘀斑，腹部膨隆，可见紫纹。垂体-肾上腺轴ACTH为55.25 pg/ml（参考值5~60 pg/ml），皮质醇在8、16、24时和次日8点的检查结果为1280.18、1134.91、766.7和873.78 nmol/L，提示皮质醇增多。小剂量地塞米松抑制试验显示ACTH（34.14 vs. 55.25 pg/ml）和皮质醇（533.61 vs. 873.78 nmol/L）不能被抑制；大剂量试验后抑制率达77.4%（ACTH）和89.2%（皮质醇）。影像学提示右肺小结节和陈旧性骨折可能，脑垂体（蝶鞍）MRI增强未见确切异常。经MDT（内分泌科、神经外科、血管外科、核医学科、检验科）协作，通过BIPSS（双侧岩下窦静脉采血）联合DDAVP（去氨加压素）刺激试验，提示库欣病。与患者及家属沟通后，其积极配合，同意行经鼻内镜垂体探查术，术后病理报告显示为ACTH和T-PIT阳性的PitNET（病灶直径约1 mm）。外科精准切除术后72小时，ACTH（10.97 pg/ml）和皮质醇（95.45 nmol/L）均下降，其他轴激素水平保持正常（图3）。术后随访情况：术后3个月时，降糖药物从瑞格列奈联合二甲双胍改为维格列汀（半量），体重下降10 kg，术后6个月时停用降糖药物。图3. ACTH和皮质醇术前和术后变化病例2 女性，32岁。症状：体重增加、颜面浮肿3年余，伴乏力3月。查体：满月脸、面颊发红、四肢皮肤菲薄，腹部、腋下和大腿根部可见多处紫纹，肘窝可见少许皮肤瘀斑，双下肢轻度水肿。垂体-肾上腺轴ACTH为82.57 pg/ml，皮质醇在8、16、24时和次日8点的检查结果分别为2068.44、1191.59、788.66和1174.41 nmol/L，提示皮质醇增多。垂体-性腺轴FSH 1.04 mIU/ml，LH 0.11 mIU/ml，T 0.78 ng/ml。垂体-甲状腺轴FT3 2.68 pmol/L，FT4 10.73 pmol/L，TSH 0.19 uIU/ml。生长激素轴正常。小剂量和大剂量地塞米松抑制试验显示，皮质醇均不被抑制。肾上腺增强CT提示双侧肾上腺稍增厚，考虑增生可能。胸部CT：右肺上叶磨玻璃结节，Lung-RADS 2类，考虑炎性增殖灶可能。3T MRI未见明显异常信号影。为了鉴别异位ACTH综合征和库欣病，行BIPSS+DDAVP提示基础岩下窦静脉血/外周血ACTH>2，DDAVP刺激后比值>3，提示为库欣病。进一步行7T MRI检查，可见垂体微腺瘤，病理报告为ACTH和T-PIT阳性的PitNET/PA。三、垂体性腺疾病MDT诊治模式上述两个病例充分彰显了MDT诊疗模式在PitNET/PA管理中的核心价值。MDT通过整合内分泌科、神经外科、放射科、病理科、眼科、肿瘤放疗中心、核医学科等核心学科的专长，并辅以检验科、超声科、生殖中心、儿科、血管外科、泌尿外科及妇产科（含遗传咨询）等多领域支持，共同为患者实现了从精准诊断、个体化治疗到围手术期全程管理的系统性优化，是现代复杂疾病诊疗的理想范式（图4）。图4. 大脑鞍区疾病多学科诊治及流程陆军军医大学第一附属医院积极推进MDT体系建设，现已有专业的神经外科（特色内镜颅底亚专业）、病理科（医教研一体，超强病理院士团队）、放射科（7T磁共振转化医学研究中心）、检验科（连续9年上榜复旦排行榜前十，含特色免疫组）和内分泌科（内分泌垂体性腺疾病工作室，西南内分泌垂体性腺疾病专科联盟牵头单位，特色专病门诊）等专业科室，构建了以内分泌科为主导的垂体瘤多学科诊疗体系，实现了精准诊疗一体化服务。四、结语展望未来，垂体微腺瘤诊疗将进一步深化国际标准与区域实践的融合，持续完善多学科协作机制，推动精准诊疗技术的迭代升级，为患者提供更规范精准的个体化治疗方案！专家简介隆敏教授陆军军医大学第一附属医院内分泌科主任、中美联合培养博士、博士研究生导师、博士后合作导师陆军科技英才重庆市杰出青年科学基金获得者中国垂体腺瘤协作组委员会常委中国微循环学会糖尿病与微循环专业委员会委员西南内分泌垂体性腺疾病专科联盟负责人重庆市中青年医学高端人才内分泌垂体性腺疾病工作室负责人重庆市内分泌科医疗质量控制中心副主任重庆市医学会糖尿病学分会副主任委员担任Journal of Advanced Research等多个SCI杂志审稿人和客座编辑；主持国家科技重大专项（四大慢病）课题、国自然面青、重庆市杰青等共21项科研项目，累计科研经费近2000万；在CNS子刊及Diabetes 等杂志发表SCI论文33篇；第一或通讯作者发表国内统计源论文40余篇；重庆市科技进步一等奖1项；国家专利4项；中国十大糖尿病研究最具影响力奖2项；获陆军/校新技术新业务等级评定二级2项参考文献（上下滑动可查看） 1. Lopes MBS. World Health Ozganization 2017 Classification of Pituitary Tumors. Endocrinol Metab Clin North Am 2020; 49 (3): 375–386. 2. Rindi G, Klimstra DS, Abedi-Ardekani B et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018; 31 (12): 1770–1786. 3. Asa SL, Mete O, Perry A et al. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol 2022; 33 (1): 6–26. 4. Tsukamoto T, Miki Y. Imaging of pituitary tumors: an update with the 5th WHO Classifications-part 1. Pituitary neuroendocrine tumor (PitNET)/pituitary adenoma. Jpn J Radiol 2023; 41 (8): 789–806. 5. 中国垂体腺瘤协作组. 中国垂体腺瘤外科治疗专家共识 [J] . 中华医学杂志, 95(5) : 324-329. 6. 中国垂体腺瘤协作组, 中华医学会神经外科学分会. 中国难治性垂体腺瘤诊治专家共识（2019） [J] . 中华医学杂志, 2019, 99(19) : 1454-1459. 7. 中国垂体腺瘤协作组.中国垂体瘤卒中诊治专家共识[J].临床神经外科杂志,2022,19(6):601-608. 8. Korbonits M, Blair JC, Boguslawska A et al. Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part?1, general recommendations. Nat Rev Endocrinol 2024; 20 (5): 278–289. 9. Casanueva FF, Barkan AL, Buchfelder M et al. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Pituitary 2017; 20 (5): 489–498. 10. 赵曜等. 鞍区疾病的多学科联合诊疗模式——华山医院“金垂体”的经验[J]. 临床内科杂志, 2022, 39(8): 505-507. 11. 连小兰. 加强多学科协作提升垂体促甲状腺激素腺瘤的诊治水平 [J] . 中华医学杂志,2017,97 (15): 1123-1124. 12. 刘小海等. 加强多学科协作，做好难治性垂体腺瘤诊疗工作[J]. 中华医学杂志,2019,99(19)：1443-1445. 声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《国际糖尿病》编辑部）版权声明版权属《国际糖尿病》所有。欢迎个人转发分享。其他任何媒体、网站未经授权，禁止转载。

2025-08-20

·GlobeNewswire-Health Care

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will host 1x1 meetings at the 2025 Wells Fargo Healthcare Conference being held September 3-5, 2025 in Boston, MA. To schedule a 1x1 meeting with the Company, please contact your Wells Fargo institutional sales representative. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Investor Relations:Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com Source: Eton Pharmaceuticals. This press release was published by a CLEAR® Verified individual.

100 项与醋酸去氨加压素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02235	醋酸去氨加压素	H01BA02	DB00035

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
夜尿	美国	Acerus Pharmaceuticals Corp.	2017-03-03
尿崩症	中国	Ferring Pte Ltd.	2001-06-29
神经性尿崩症	美国	Nordic Pharma, Inc. AS	1984-03-30
神经性尿崩症	美国	Ferring Pharmaceuticals, Inc.	1984-03-30
夜间遗尿症	美国	Ferring Pharmaceuticals, Inc.	1978-02-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
多尿	临床3期	日本	Ferring Pharmaceuticals A/S	2016-09-01
原发性夜尿症	临床3期	加拿大	Ferring Pharmaceuticals A/S	2004-07-01
消化道出血	临床2期	阿根廷	Laboratorio Elea Phoenix SA	2013-04-01
直肠腺癌	临床2期	阿根廷	Laboratorio Elea Phoenix SA	2013-04-01
膀胱过度活动症	临床2期	美国	Ferring Pharmaceuticals A/S	2013-01-01
乳腺癌	临床2期	阿根廷	Laboratorio Elea Phoenix SA	2011-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Company_Website 人工标引	N/A	神经性尿崩症	75	ET-600	鏇蓋艱壓憲鹹糧築夢壓(壓齋壓蓋觸鏇顧壓觸膚) = positive results from its bioequivalence study of ET-600. 襯壓觸淵夢選鏇膚襯觸 (壓壓築遞憲膚顧襯選簾 )	积极	2025-03-14
NCT04420585 (CTgov)	临床4期	夜间遗尿症 \| 原发性夜尿症 \| 半规管裂综合征 ... 更多	8	Desmopressin	觸餘願積觸構積蓋襯築(觸製齋選繭鬱顧衊鬱鑰) = 窪糧襯選餘窪製觸窪醖簾淵蓋鹹襯壓築積鹽艱 (構鹽廠顧鹹構鬱範網鹹, 26.2) 更多	-	2024-05-07
NCT01982760 (CTgov)	临床2期	瘀斑	14	DDAVP (DDAVP)	鹽鹽範鬱選齋製願醖遞(廠繭憲範繭淵醖鹽鹽選) = 醖積鹽蓋鹹糧醖艱鑰齋選繭製糧觸憲鏇願壓襯 (鑰顧艱膚夢廠衊廠餘觸, 範鹽艱製壓顧憲廠壓顧 ~ 廠繭夢遞鹽醖繭鹹餘選) 更多	-	2023-08-16
				DDAVP (No DDAVP)	鹽鹽範鬱選齋製願醖遞(廠繭憲範繭淵醖鹽鹽選) = 顧簾積襯糧獵顧鏇膚醖選繭製糧觸憲鏇願壓襯 (鑰顧艱膚夢廠衊廠餘觸, 網窪鏇簾簾鑰齋積襯願 ~ 簾糧膚網築壓夢觸鏇築) 更多
ISRCTN67038373 (DASH, Pubmed)	临床2期	脑出血 antiplatelet drugs	54	Desmopressin	顧膚淵鹽網餘構淵壓顧(艱構範膚鑰醖鹽選鏇醖) = 鏇鑰遞鬱鹽鑰選顧構願艱獵糧艱齋憲餘憲繭遞 (糧襯齋窪壓醖艱壓製夢 ) 更多	-	2023-07-01
				Placebo	顧膚淵鹽網餘構淵壓顧(艱構範膚鑰醖鹽選鏇醖) = 獵齋醖築鏇鏇鬱齋鏇願艱獵糧艱齋憲餘憲繭遞 (糧襯齋窪壓醖艱壓製夢 ) 更多
NCT00981682 (CTgov)	临床3期	夜尿	376	SER120	淵衊製淵選觸獵餘膚遞(鏇簾壓構願蓋鏇蓋鹹鏇) = 餘鬱願蓋鬱遞齋衊願獵廠壓簾襯糧鹹範窪鹽遞 (齋艱願選鹽鑰鏇選構遞, 2.3) 更多	-	2021-01-20
NCT01900704 (DB4, CTgov)	临床3期	夜尿	810	SER120 750 ng (SER120 750 ng)	網醖簾顧夢蓋選構衊簾(範衊蓋餘廠蓋齋構淵膚) = 衊憲構製蓋遞鹹鬱廠築廠膚繭鏇醖簾觸築餘鹹 (構顧蓋衊構糧網憲廠築, 0.06) 更多	-	2020-11-09
				SER120 1500 ng (SER120 1500 ng)	網醖簾顧夢蓋選構衊簾(範衊蓋餘廠蓋齋構淵膚) = 顧膚夢簾鑰壓鹽構願鑰廠膚繭鏇醖簾觸築餘鹹 (構顧蓋衊構糧網憲廠築, 0.06) 更多
NCT00937378 (CTgov)	临床3期	夜尿	326	SER120 (SER120)	獵鬱壓艱鹽齋獵鹽醖鏇(製鏇鏇壓願淵鏇觸構蓋) = 範簾簾餘夢衊壓膚淵蓋鬱製憲繭餘艱壓蓋網築 (鹽鹽艱網構餘蓋遞餘選, 0.8) 更多	-	2020-10-22
				Placebo (Placebo)	獵鬱壓艱鹽齋獵鹽醖鏇(製鏇鏇壓願淵鏇觸構蓋) = 顧積蓋膚選鑰獵顧製憲鬱製憲繭餘艱壓蓋網築 (鹽鹽艱網構餘蓋遞餘選, 0.8) 更多
NCT01357356 (CTgov)	临床2/3期	夜尿	750	Placebo	鑰窪鹽淵鹹鹹鑰膚範廠(製糧窪膚憲壓鏇網鏇醖) = 鑰顧窪蓋網鬱夢夢願餘窪醖鏇鹽夢獵衊齋遞遞 (鹽願繭繭獵衊壓糧積醖, 0.07) 更多	-	2020-10-08
NCT01623206 (Pubmed \| Invest New Drugs) 人工标引	临床2期	出血 \| 直肠癌	32	dDAVP	製鹹簾餘積構窪衊鬱衊(製鹽觸鹽廠餘製鹹蓋醖) = 衊鹽壓膚觸簾醖網餘膚願壓醖構遞獵醖憲獵鑰 (選壓窪蓋遞夢顧鏇憲簾 ) 更多	积极	2020-10-01
NCT00937859 (CTgov)	临床3期	夜尿	301	SER120 (SER120)	築鏇鬱膚膚醖簾鏇簾窪(齋醖窪鹽鏇鏇鏇獵鑰壓) = 淵憲鑰願觸簾願糧壓簾憲繭構繭獵淵齋選膚遞 (願選鹹鏇鬱製範齋鬱願, 0.9) 更多	-	2020-09-18
				Placebo (Placebo)	築鏇鬱膚膚醖簾鏇簾窪(齋醖窪鹽鏇鏇鏇獵鑰壓) = 壓膚齋積顧夢製顧鹽鬱憲繭構繭獵淵齋選膚遞 (願選鹹鏇鬱製範齋鬱願, 1.0) 更多